Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BSX NASDAQ:DXCM NYSE:EW NASDAQ:LNTH NYSE:MDT NYSE:SYK NASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSXBoston Scientific$57.08+0.7%$62.21$52.52▼$109.50$84.22B0.6218.78 million shs12.84 million shsDXCMDexCom$71.90+0.6%$63.46$54.11▼$89.98$27.57B1.46.68 million shs9.08 million shsEWEdwards Lifesciences$83.24+0.3%$81.41$72.30▼$87.89$47.77B0.875.21 million shs3.73 million shsLNTHLantheus$94.47-1.7%$83.21$47.25▼$98.27$6.26B-0.081.02 million shs711,063 shsMDTMedtronic$78.110.0%$83.71$74.40▼$106.33$100.34B0.629.94 million shs9.23 million shsSYKStryker$313.48-2.5%$325.81$281.00▼$404.87$123.25B0.82.91 million shs2.89 million shsTMDXTransMedics Group$68.85+1.3%$99.38$60.10▼$156.00$2.35B2.071.91 million shs988,201 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSXBoston Scientific-0.33%+6.74%-7.23%-25.35%-46.87%DXCMDexCom+6.71%+21.97%+10.55%-1.15%-18.20%EWEdwards Lifesciences+0.87%+1.65%+1.66%+5.10%+6.46%LNTHLantheus+3.44%-0.38%+14.43%+31.31%+25.07%MDTMedtronic-0.53%+2.50%-8.29%-19.98%-9.40%SYKStryker+1.00%+6.24%-5.07%-13.86%-17.55%TMDXTransMedics Group+2.83%+5.95%-39.89%-48.83%-45.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSXBoston Scientific$57.08+0.7%$62.21$52.52▼$109.50$84.22B0.6218.78 million shs12.84 million shsDXCMDexCom$71.90+0.6%$63.46$54.11▼$89.98$27.57B1.46.68 million shs9.08 million shsEWEdwards Lifesciences$83.24+0.3%$81.41$72.30▼$87.89$47.77B0.875.21 million shs3.73 million shsLNTHLantheus$94.47-1.7%$83.21$47.25▼$98.27$6.26B-0.081.02 million shs711,063 shsMDTMedtronic$78.110.0%$83.71$74.40▼$106.33$100.34B0.629.94 million shs9.23 million shsSYKStryker$313.48-2.5%$325.81$281.00▼$404.87$123.25B0.82.91 million shs2.89 million shsTMDXTransMedics Group$68.85+1.3%$99.38$60.10▼$156.00$2.35B2.071.91 million shs988,201 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSXBoston Scientific-0.33%+6.74%-7.23%-25.35%-46.87%DXCMDexCom+6.71%+21.97%+10.55%-1.15%-18.20%EWEdwards Lifesciences+0.87%+1.65%+1.66%+5.10%+6.46%LNTHLantheus+3.44%-0.38%+14.43%+31.31%+25.07%MDTMedtronic-0.53%+2.50%-8.29%-19.98%-9.40%SYKStryker+1.00%+6.24%-5.07%-13.86%-17.55%TMDXTransMedics Group+2.83%+5.95%-39.89%-48.83%-45.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSXBoston Scientific 2.93Moderate Buy$92.7162.41% UpsideDXCMDexCom 2.92Moderate Buy$82.2114.34% UpsideEWEdwards Lifesciences 2.79Moderate Buy$95.6514.92% UpsideLNTHLantheus 2.73Moderate Buy$99.715.55% UpsideMDTMedtronic 2.58Moderate Buy$106.4536.28% UpsideSYKStryker 2.73Moderate Buy$395.4826.16% UpsideTMDXTransMedics Group 2.50Moderate Buy$135.0096.08% UpsideCurrent Analyst Ratings BreakdownLatest DXCM, TMDX, LNTH, SYK, EW, BSX, and MDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026MDTMedtronic The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$84.005/19/2026BSXBoston Scientific Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$78.00 ➝ $75.005/18/2026DXCMDexCom Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$100.00 ➝ $82.005/18/2026DXCMDexCom BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingUnderweight$67.00 ➝ $64.005/18/2026BSXBoston Scientific Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$77.005/18/2026BSXBoston Scientific Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$105.00 ➝ $68.005/18/2026BSXBoston Scientific BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/18/2026DXCMDexCom Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $80.005/15/2026DXCMDexCom William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/13/2026BSXBoston Scientific Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/11/2026DXCMDexCom BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$77.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSXBoston Scientific$20.07B4.23$4.07 per share14.04$17.57 per share3.25DXCMDexCom$4.66B5.95$2.79 per share25.80$7.66 per share9.39EWEdwards Lifesciences$6.07B7.90$2.86 per share29.10$17.94 per share4.64LNTHLantheus$1.54B3.99$6.28 per share15.05$18.62 per share5.07MDTMedtronic$33.54B2.99$7.75 per share10.08$37.62 per share2.08SYKStryker$25.12B4.78$16.47 per share19.03$59.94 per share5.23TMDXTransMedics Group$605.49M3.93$3.98 per share17.32$14.29 per share4.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSXBoston Scientific$2.90B$2.3923.8815.221.0417.29%19.17%10.77%7/29/2026 (Estimated)DXCMDexCom$836.30M$2.3430.7323.811.1819.31%33.33%13.19%7/29/2026 (Estimated)EWEdwards Lifesciences$1.07B$1.8844.2724.852.0817.39%15.19%11.71%7/23/2026 (Estimated)LNTHLantheus$233.56M$4.1522.7617.53N/A18.05%29.32%15.00%8/5/2026 (Estimated)MDTMedtronic$4.66B$3.5921.7612.851.8613.00%14.82%7.88%6/3/2026 (Estimated)SYKStryker$3.25B$8.6436.2818.852.0313.20%23.42%11.04%7/30/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4015.6518.97N/A27.04%22.38%8.46%7/30/2026 (Estimated)Latest DXCM, TMDX, LNTH, SYK, EW, BSX, and MDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2026Q4 2026MDTMedtronic$1.57N/AN/AN/A$9.62 billionN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 million4/30/2026Q1 2026DXCMDexCom$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion4/30/2026Q1 2026SYKStryker$2.98$2.60-$0.38$1.93$6.34 billion$6.02 billion4/23/2026Q1 2026EWEdwards Lifesciences$0.7280$0.78+$0.0520$0.66$1.60 billion$1.65 billion4/22/2026Q1 2026BSXBoston Scientific$0.7930$0.80+$0.0070$0.90$5.19 billion$5.20 billion2/26/2026Q4 2025LNTHLantheus$1.17$1.67+$0.50$0.82$367.03 million$406.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBSXBoston ScientificN/AN/AN/AN/AN/ADXCMDexComN/AN/AN/AN/AN/AEWEdwards LifesciencesN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AMDTMedtronic$2.843.64%+5.33%79.11%49 YearsSYKStryker$3.521.12%+7.58%40.74%32 YearsTMDXTransMedics GroupN/AN/AN/AN/AN/ALatest DXCM, TMDX, LNTH, SYK, EW, BSX, and MDT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/6/2026SYKStrykerquarterly$0.881.2%6/30/20266/30/20267/31/20263/5/2026MDTMedtronicquarterly$0.713.26%3/27/20263/27/20264/17/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSXBoston Scientific0.421.901.22DXCMDexCom0.421.951.64EWEdwards Lifesciences0.064.423.63LNTHLantheus0.472.832.64MDTMedtronic0.572.541.87SYKStryker0.622.111.25TMDXTransMedics Group1.706.746.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSXBoston Scientific89.07%DXCMDexCom97.75%EWEdwards Lifesciences79.46%LNTHLantheus99.06%MDTMedtronic82.06%SYKStryker77.09%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipBSXBoston Scientific0.34%DXCMDexCom0.28%EWEdwards Lifesciences0.31%LNTHLantheus1.70%MDTMedtronic0.26%SYKStryker4.60%TMDXTransMedics Group6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSXBoston Scientific59,0001.49 billion1.48 billionOptionableDXCMDexCom11,000385.87 million384.79 millionOptionableEWEdwards Lifesciences16,000575.80 million574.02 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableMDTMedtronic95,0001.28 billion1.28 billionOptionableSYKStryker56,000383.36 million365.73 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableDXCM, TMDX, LNTH, SYK, EW, BSX, and MDT HeadlinesRecent News About These CompaniesTransMedics Shareholders Reelect Board and Approve Executive PayMay 21 at 6:30 PM | tipranks.comTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 21 at 4:05 PM | prnewswire.comTransMedics Group Signals Growth Amid Margin SqueezeMay 21 at 12:15 PM | theglobeandmail.comTransMedics Group (NASDAQ:TMDX) Gains Momentum In Healthcare SpaceMay 19 at 6:06 PM | kalkinemedia.comKTransMedics to Present at the William Blair 46th Annual Growth Stock ConferenceMay 19 at 4:05 PM | prnewswire.comTransMedics Group (NASDAQ:TMDX) Shares Up 7.1% - Here's What HappenedMay 18 at 1:13 PM | marketbeat.comTransMedics Group (TMDX) price target decreased by 22.22% to 126.07May 14, 2026 | msn.comTransMedics Group (NASDAQ:TMDX) Reaches New 52-Week Low - Here's WhyMay 12, 2026 | marketbeat.comAssessing TransMedics Group (TMDX) Valuation After A Sharp One Year Share Price DeclineMay 11, 2026 | finance.yahoo.comWall Street Zen Downgrades TransMedics Group (NASDAQ:TMDX) to SellMay 9, 2026 | marketbeat.comTransMedics Group, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comTransMedics Group Inc (TMDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid ...May 8, 2026 | finance.yahoo.comTransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of "Moderate Buy" by BrokeragesMay 8, 2026 | marketbeat.comTransMedics Group (TMDX) Gets a Buy from NeedhamMay 7, 2026 | theglobeandmail.comTransMedics Group Stock Watch: Healthcare Growth in FocusMay 6, 2026 | kalkinemedia.comKTransMedics tumbles after earnings missMay 6, 2026 | seekingalpha.comTransMedics: Cheaper, But Still Priced For PerfectionMay 6, 2026 | seekingalpha.comTransMedics Group (NASDAQ:TMDX) Given New $124.00 Price Target at Canaccord Genuity GroupMay 6, 2026 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Lowered to $120.00 at TD CowenMay 6, 2026 | marketbeat.comStifel Nicolaus Cuts TransMedics Group (NASDAQ:TMDX) Price Target to $85.00May 6, 2026 | marketbeat.comTMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins FallMay 6, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Stocks to Buy in May Before the Next AI Surge HitsBy Thomas Hughes | May 1, 2026Roblox Stock Slides to New Low as Safety Changes Weigh on OutlookBy Jennifer Ryan Woods | May 3, 2026NVIDIA’s China Connection: Investor Risks With Earnings AheadBy Thomas Hughes | May 5, 2026Verizon’s Signal Strength: The Turnaround Call Is Loud and ClearBy Jeffrey Neal Johnson | April 30, 2026Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?By Ryan Hasson | May 12, 2026DXCM, TMDX, LNTH, SYK, EW, BSX, and MDT Company DescriptionsBoston Scientific NYSE:BSX$57.08 +0.41 (+0.73%) Closing price 03:59 PM EasternExtended Trading$57.61 +0.53 (+0.92%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.DexCom NASDAQ:DXCM$71.90 +0.46 (+0.64%) Closing price 04:00 PM EasternExtended Trading$72.03 +0.13 (+0.17%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Edwards Lifesciences NYSE:EW$83.24 +0.27 (+0.32%) Closing price 03:59 PM EasternExtended Trading$83.24 0.00 (0.00%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Lantheus NASDAQ:LNTH$94.47 -1.62 (-1.69%) Closing price 04:00 PM EasternExtended Trading$94.48 +0.00 (+0.01%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Medtronic NYSE:MDT$78.11 -0.04 (-0.05%) Closing price 03:59 PM EasternExtended Trading$78.10 -0.02 (-0.02%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.Stryker NYSE:SYK$313.48 -8.01 (-2.49%) Closing price 03:59 PM EasternExtended Trading$313.95 +0.47 (+0.15%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.TransMedics Group NASDAQ:TMDX$68.85 +0.85 (+1.25%) Closing price 04:00 PM EasternExtended Trading$68.63 -0.22 (-0.33%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
